Earnings
Shares of Novartis are down nearly 3 percent this morning after the company reported a sharp decline in generic drugs and sales results from key branded medicines that missed analysts’ projections for the first quarter.
Abbott today announced financial results for the first quarter ending March 31, 2018 and is off to a strong start to the year.
Johnson & Johnson reported a strong first quarter with $20 billion in sales that was fueled by significant growth in its pharmaceuticals business.
Reinforced cash position finances operations through key clinical milestones to mid-2019, phase IIb clinical programs for ABX464 in HIV and IBD patients expected to be initiated around end of 2018.
Here’s a look at eight biopharma companies with upcoming catalysts.
OPKO Health’s fourth-quarter report highlighted positive activities in the face of a net loss of $213.9 million during the most recent quarter.
It took more than 8 months and a series of sweetened offers, but Sanofi was able to close their $11.6B deal to buy Bioverativ without triggering an auction.
Less than two months into the year, Teva’s new chief has already effectively written off a recovery for 2018.
The company goes “above and beyond” with staggering 7% or greater dividend raises over 25 years.
AbbVie provided an unexpectedly strong 2018 guidance revision, largely built on the new corporate tax rate.
PRESS RELEASES